Kura Oncology financials
$10.81+1.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | $67.4M | $53.9M | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross margin | 99.9% | 100.0% | — | — | — | — | — | — | — | — |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M | -$131.3M | -$91.9M | -$67.5M | -$62.9M | -$36.1M | -$28.4M |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M | -$89.6M | -$63.1M | -$60.4M | -$35.4M | -$27.6M |
| Net margin | −412.9% | −322.9% | — | — | — | — | — | — | — | — |
| Diluted EPS | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 | $-1.69 | $-1.51 | $-1.72 | $-1.52 | $-1.47 |
| EBITDA | -$302.6M | -$192.3M | -$165.0M | -$139.1M | -$130.7M | -$91.7M | -$67.5M | -$62.9M | -$36.0M | -$28.3M |
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M | -$69.8M | -$54.8M | -$48.7M | -$28.4M | -$25.3M |
| Free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M | -$105.7M | -$72.0M | — | — | — | — |
| Diluted shares | 87.7M | 86.2M | 73.2M | 67.0M | 66.4M | 53.1M | 41.9M | 35.2M | 23.2M | 18.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $149.1M | $224.5M | $37.3M | $51.8M | $90.7M | $325.5M |
| Short-term investments | $518.1M | $502.9M | $386.6M | $386.2M | $427.3M | $307.8M |
| Total debt | $9.7M | $9.5M | $9.3M | $9.2M | $0.00 | $7.3M |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M | $647.2M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M | $36.3M |
| Shareholders' equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M | $610.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology